# C_2011322EN.01001501.xml

| 5.11.2011 | EN | Official Journal of the European Union | C 322/15 |
| --- | --- | --- | --- |

5.11.2011

EN

Official Journal of the European Union

C 322/15

---

Prior notification of a concentration

(Case COMP/M.6423 — Carlyle/H&F/Pharmaceutical Product Development)

Candidate case for simplified procedure

(Text with EEA relevance)

2011/C 322/06

| 1. | On 26 October 2011, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Carlyle Partners V, L.P. (USA), a fund managed by the Carlyle Group (‘Carlyle’), and investment fund affiliates controlled by H&F Corporate Investors VII, Ltd. (Cayman Islands) and sponsored by Hellman & Friedman (‘H&F’) acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of Pharmaceutical Product Development, Inc. (USA) by way of purchase of shares. |
| --- | --- |

1.

On 26 October 2011, the Commission received a notification of a proposed concentration pursuant to Article 4 of Council Regulation (EC) No 139/2004 (1) by which the undertaking Carlyle Partners V, L.P. (USA), a fund managed by the Carlyle Group (‘Carlyle’), and investment fund affiliates controlled by H&F Corporate Investors VII, Ltd. (Cayman Islands) and sponsored by Hellman & Friedman (‘H&F’) acquire within the meaning of Article 3(1)(b) of the Merger Regulation joint control of Pharmaceutical Product Development, Inc. (USA) by way of purchase of shares.

1

| 2. | The business activities of the undertakings concerned are:






  — | for Carlyle: global alternative asset manager, which sponsors funds that invest globally across four investment disciplines (buyout, credit alternatives, growth capital and real estate) in a range of industries, |
| --- | --- | --- |

2.

The business activities of the undertakings concerned are:

—

for Carlyle: global alternative asset manager, which sponsors funds that invest globally across four investment disciplines (buyout, credit alternatives, growth capital and real estate) in a range of industries,

| — | for H&F: private equity investment firm which focuses on investing in business franchises and serving as a partner to management in select industries including healthcare, business & marketing services, software, financial services, internet & digital media, insurance, media and energy & industrials, |
| --- | --- |

—

for H&F: private equity investment firm which focuses on investing in business franchises and serving as a partner to management in select industries including healthcare, business & marketing services, software, financial services, internet & digital media, insurance, media and energy & industrials,

| — | for Pharmaceutical Product Development: contract research organization, which provides laboratory and clinical development services to the pharmaceutical industry. |
| --- | --- |

—

for Pharmaceutical Product Development: contract research organization, which provides laboratory and clinical development services to the pharmaceutical industry.

| 3. | On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the EC Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the EC Merger Regulation (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice. |
| --- | --- |

3.

On preliminary examination, the Commission finds that the notified transaction could fall within the scope of the EC Merger Regulation. However, the final decision on this point is reserved. Pursuant to the Commission Notice on a simplified procedure for treatment of certain concentrations under the EC Merger Regulation (2) it should be noted that this case is a candidate for treatment under the procedure set out in the Notice.

2

| 4. | The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.
  Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.6423 — Carlyle/H&F/Pharmaceutical Product Development, to the following address:





  European Commission |
| --- | --- |
| Directorate-General for Competition |
| Merger Registry |
| J-70 |
| 1049 Bruxelles/Brussel |
| BELGIQUE/BELGIË |

4.

The Commission invites interested third parties to submit their possible observations on the proposed operation to the Commission.

Observations must reach the Commission not later than 10 days following the date of this publication. Observations can be sent to the Commission by fax (+32 22964301), by email to COMP-MERGER-REGISTRY@ec.europa.eu or by post, under reference number COMP/M.6423 — Carlyle/H&F/Pharmaceutical Product Development, to the following address:

European Commission

Directorate-General for Competition

Merger Registry

J-70

1049 Bruxelles/Brussel

BELGIQUE/BELGIË

---

(1)  OJ L 24, 29.1.2004, p. 1 (the ‘EC Merger Regulation’).

1

(2)  OJ C 56, 5.3.2005, p. 32 (‘Notice on a simplified procedure’).

2

---